ReviewDrug design, development and therapy2022
Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations.
Review in Drug design, development and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- The impact of fluoxetine on obesity and diabetes-related biomarkers in overweight and obese individuals: a systematic review and meta-analysis of randomized controlled trials.BMC psychiatry · 2025Pooled it
- Role of Incretin Mimetics in Cardiovascular Outcomes and Other Classical Cardiovascular Risk Factors beyond Obesity and Diabetes Mellitus in Nondiabetic Adults with Obesity: a Meta-analysis of Randomized Controlled Trials.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025Pooled it
- Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review.International journal of molecular sciences · 2024Pooled it
- Effect of Silibinin on Human Pancreatic Lipase Inhibition and Gut Microbiota in Healthy Volunteers: A Randomized Controlled Trial.International journal of molecular sciences · 2024Trial
- Strategies to Improve the Lipophilicity of Hydrophilic Macromolecular Drugs.Advanced healthcare materials · 2026Review
- The Effect of Semaglutide With Lifestyle Intervention on the Physical Health of Patients Treated With Antipsychotic Drugs in a Secure Mental Health Setting: Protocol for an Uncontrolled Pretest-Posttest Pilot Mixed Methods Study.JMIR research protocols · 2025Article
- Advancements and challenges in the management of obesity using pharmacotherapy (Review).Experimental and therapeutic medicine · 2025Review
- Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide.American heart journal plus : cardiology research and practice · 2025Review
- Pregnancy Outcomes After Semaglutide Exposure.Basic & clinical pharmacology & toxicology · 2025Article
- Article
- A comparison of Glucagon-like peptide-1 receptor agonists on weight change, side effects, and quality of life in Kuwait.Frontiers in nutrition · 2025Article
- Obesity and Its Comorbidities: Current Treatment Options, Emerging Biological Mechanisms, Future Perspectives and Challenges.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Review
- Semaglutide: Double-edged Sword with Risks and Benefits.Archives of internal medicine research · 2025Article
- Semaglutide use in people with obesity and type 2 diabetes from real-world utilization data: An analysis of the All of US Program.Diabetes, obesity & metabolism · 2024Article
- Review
- Article
- Advantages and Limitations of the Body Mass Index (BMI) to Assess Adult Obesity.International journal of environmental research and public health · 2024Review
- Semaglutide-induced Hyperemesis Gravidarum.JCEM case reports · 2024Article
- Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity.Frontiers in nutrition · 2024Review
- Cardiovascular Implications of Semaglutide in Obesity Management: Redefining Cardiovascular Health Strategies.Heart international · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Losses of 5-10% or more of initial body weight are associated with improvements in obesity-related comorbidities. However, attaining and sustaining this level of weight loss is challenging. The novel anti-obesity medication semaglutide 2.4 mg injected subcutaneously once weekly as an adjunct to a reduced-calorie diet and physical activity helps patients achieve average losses of 9.6-17.4% of initial body weight at week 68, as well as improvements in cardiometabolic and psychosocial indices. Despite these average benefits, prescribers should carefully assess the suitability of patients for this medication. In this paper, we discuss considerations for the selection of individuals who are candidates for semaglutide and special considerations related to the use of this medication. These include its efficacy and safety, as well as its contraindications, potential adverse effects, management of comorbidities and drug interactions, insurance coverage and cost, and patient preferences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.